Phase 2b Trial Data on Treatment for Inflammation Due Soon
Research Report

1. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor/employee.
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 

For additional disclosures, please click here.

Disclosures for Roth Capital and Revelation Biosciences Inc., June 5, 2025:

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

For important disclosure information regarding the companies in this summary report, please contact the Director of Research at (800) 678-9147 or write to: ROTH Capital Partners, LLC, Attention: Director of Research, 888 San Clemente Drive, Newport Beach, CA 92660

Disclosures: Within the last twelve months, ROTH Capital Partners, or an affiliate to ROTH Capital Partners, has received compensation for investment banking services from Revelation Biosciences, Inc.. ROTH makes a market in shares of Revelation Biosciences, Inc. and as such, buys and sells from customers on a principal basis. Shares of Revelation Biosciences, Inc. may be subject to the Securities and Exchange Commission's Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities. Shares of Revelation Biosciences, Inc., (REVB) may be subject to the Securities and Exchange Commission's Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities

ROTH Capital Partners, LLC and its affiliates expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months. The material, information and facts discussed in this report other than the information regarding ROTH Capital Partners, LLC and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This report should not be used as a complete analysis of the company, industry or security discussed in the report. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this report are subject to change without notice. An investment in the stock may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, an investment in the stock may involve a high degree of risk and may not be suitable for all investors. No part of this report may be reproduced in any form without the express written permission of ROTH. Copyright 2025. Member: FINRA/SIPC.

Revelation Biosciences Inc. (REVB: NASDAQ) is about to release topline data from the Phase 1b PRIME (PRotective IMmunostimulatory Evaluation) trial evaluating Gemini in patients with chronic kidney disease, reported Dr. Jonathan Aschoff, managing director and senior research analyst, ROTH Capital Partners, in a June 5 research note. 

Gemini is Revelation's lead clinical candidate, an intravenously administrated, proprietary formulation of PHAD, or phosphorylated hexaacyl disaccharide, explained Aschoff. This potential therapy decreases inflammation-caused damage by reprogramming the innate immune system to respond to stress, such as trauma and infection, less intensely.

2,253% Upside Possible

At the time of Aschoff's report, Revelation was trading at about $0.85 per share. In comparison, ROTH's target on the biopharma firm is $20 per share. Thus, the target implies a potential return of 2,253%.

Revelation is a Buy.

Cashed Up for 2025

The life sciences firm has enough cash to continue advancing its clinical programs into Q1/26, noted Aschoff. At the end of Q1/25, Revelation had $7.3 million ($7.3M), consisting of $3.7M in cash and $3.6M in net proceeds from the recent equity financing, reported Aschoff. This is enough to fund the biotech to Q1/26, according to ROTH's estimates.

New Indication Added

Revelation Bioscience is developing Gemini for multiple indications and just announced another: post burn infections. The biotech, reported the analyst, will evaluate Gemini as a treatment for preventing infection in burns severe enough to require hospitalization. Gemini's clinical biomarker activity was shown to strongly correlate to the benefits seen in preclinical models of burn infection, specifically, a significant reduction in the severity and duration of a Pseudomonas lung infection and an overall decrease in inflammation.

Further Study Underway

Gemini's protective effects against inflammation were exhibited in a recent study, Revelation announced in March. In that, human peripheral blood mononuclear cells (PMBCs) were primed with either Gemini or placebo and then challenged with clinically relevant inflammation promoters. These activators were high mobility nbox protein-1, or HMGB-1, generated by tissue injury, and lipopolysaccharide, or LPS, generated by bacterial infection, in vitro.

After exposing Gemini-primed PMBCs to two different doses of either of these proinflammatory agents, levels of multiple proinflammatory and anti-inflammatory cytokines including Interleukin-1B (IL-1b), tumor necrosis factor-alpha (TNFa), IL-6, IL-1RA and IL-10 were measured. As shown in the results, Gemini priming significantly decreased proinflammatory cytokines and materially increased anti-inflammatory cytokines (such as IL-1RA and IL-10).

These outcomes bode well for Gemini performing as expected in the target indications in the biotech's Phase 1b PRIME trial underway (started in January 2025). This U.S.-based, multisite, placebo-controlled study, eventually will encompass 40 enrolled patients, with stage 3 and 4 chronic kidney disease, in up to five dose cohorts. In this study, PBMCs are being collected from participating patients and subjected to the same HMGB-1 and LPS analyses as in the preceding study. The objective is to demonstrate the same attenuated response to HMGB-1 and LPS ex vivo versus placebo in chronic kidney disease patients.

Topline data, including safety, tolerability and protection against pro-inflammatory agents, are expected in mid-2025.

More Stock Details

Aschoff reported that at the time of his report, Revelation had 960,000 shares outstanding. Its market cap was $850,000. Its 52-week range was $0.85–38.40 per share.